Form 4: ANI Pharma Exec Sells Shares Under 10b5-1 Plan

Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals Inc., sold 500 shares of common stock for $84.33 per share as part of a pre-arranged trading plan.

Summary

• Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals Inc. (ANIP), reported a sale of common stock.
• The transaction involved the disposition of 500 shares of ANIP common stock.
• The shares were sold at a price of $84.33 per share.
• The sale occurred on January 13, 2026.
• Following this transaction, Meredith Cook beneficially owns 74,374 shares of ANIP common stock directly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on September 15, 2025.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale conducted under a pre-arranged 10b5-1 trading plan, which mitigates any negative sentiment typically associated with insider selling. It does not reflect new information about the company's performance or outlook.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, non-public information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived as a lack of confidence by some investors, though this is largely mitigated by the 10b5-1 plan.

Risks

• No specific risks are mentioned in the filing other than the routine disclosure of an insider stock sale.

Future Outlook

This filing reports a past transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction disclosure for an executive at a pharmaceutical company. Such filings are common across all industries for public company insiders managing their equity holdings, often through pre-arranged trading plans.

Stakeholder Impact

• Shareholders: A minor, pre-planned insider sale is unlikely to have a significant impact on shareholder sentiment or the stock price. It is a routine disclosure.

Key Dates

Recommendation

The filing reports a routine, pre-planned insider sale under a Rule 10b5-1 plan. This type of transaction is generally not indicative of a change in the company's fundamentals or management's confidence, and therefore does not warrant a change in investment recommendation based solely on this filing. Investors should continue to monitor broader company performance and market conditions.

Keywords

ANI Pharmaceuticals, ANIP, Meredith Cook, Form 4, insider trading, stock sale, 10b5-1 plan, beneficial ownership, pharmaceutical